Exhibit 99.1 Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues CAMBRIDGE, Mass., Jan. 12, 2026 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44 thAnnual J.P. Morgan Healthcare Conference in San Francisco ...